We describe the development and validationof a one-step nonradioactive immunoassay for free thyroxine (Amerhte-MAB FT4) in serum or plasma, inthe dedicated Amerlit&' enhanced luminescence assay system. A monoclonal antibody to thyroxine (T4), conjugated with horseradish peroxidase (HRP; EC 1.11.1.7), competes for bindingwith Fr4 or with a conjugate of a protein and L-tniodothyronineimmobilized onto the surface of the assay microwells. The signal is generated by antibody-HRP bound to the protein-T3 conjugate, with luminol as substrate. The assay design exploits the high sensitivityof luminescence signal detection, permitting minimal sample dilution and T4 sampling by the antibody. It withstands progressive dilutionof serum and is unaffected by T4-binding proteins in serum. The disclosure and validation of this FT4 assay follows guidelines recommended by the American Thyroid Association (Clin Chem 1991 ;37:2002-8).
jugate and volumes of added buffer relative to the volume of serum. Limited T4 sequestration by the antibody and low sample dilution in the assay uphold two key criteria for valid FT4 assays (11-14).
The Committee on Nomenclature of the American Thyroid Association has made recommendations on FT.4 assay development (14) . Disclosure of test mechanisms is encouraged and guidelines on validation procedures for FT4 assays are provided. These guidelines emphasize the desirability of (a) minimal dilution of the specimen measured in the assay, (b) provision of data on antibody affinity (both for T4 and any binding competitor), (c) proof of assay insensitivity to any changes in the concentration of any serum T4-binding protein, (d) demonstration of acceptably small T4 sampling by the antibody probe, and (e) a resulting robustness (near-constancy of Fr4 estimate) with progressive dilution of serum. Assay ingredients (especially the nature of the tracer probe), precision, sensitivity, specificity, and resistance to potential interference, plus a comprehensive evaluation of the assay in a wide range of diagnostic settings, are also required to be disclosed. Developers of FT., assays are encouraged to produce methods conforming closely to the performance of socalled "gold standards" such as equilibrium dialysis, ultrafiltration, or two-step FT4 assays (14) . However, the gold standards have their own inconsistencies and areas of technical weakness (15-22).
In spite of the problems of making definitive comparisons, we have followed the guidelines of the Association (14) in the description of the assay and validation of its performance in this and the accompanying paper (23).
MaterIals and Methods
The assay was designed specifically for the Kodak wells were then washed again and assayed as described above.
Determination of assay B0. We estimated %B and B0 by a special protocol. HRP-IgG conjugate solution, diluted with water to the recommended working strength (0.01 mol/L), was added to assay wells (0.01 mL); signal generation reagent was then added as in the standard assay, and the luminescence was measured in the luminometer ("total" light emission by the added conjugate). We similarly measured the zero calibrator by pipetting 25 L of calibrator and 0.1 mL of working-strength antibody-conjugate solution; after 30 min of incubation at 37#{176}C, the wells were washed as described above, and luminol solution was added. The resulting light emission was divided by that of the wells emitting the total signal, to give the effective B, of the assay (32.7% Fig. 3) . Serum from a patient with low concentrations of both TBG and HSA will be more sensitive to NEFA, which is in agreement with results of equilibrium dialysis and two-step immunoassays (27) (28) (29) (30) (31) . Therefore, it is important to minimize the production of NEFA in vitro during sample collection and storage. Unpublished data on ifie at Kodak Clinical Diagnostics show that, for serum from euthyroid subjects (n = 10), samples can be stored at 2-8#{176}C for as long asS days and at -20#{176}C indefinitely without adverse effects. In vivo samples from subjects receiving heparin therapy must be stored immediately at -20#{176}C to minimize rapid production of NEFA in vitro (27) (28) (29) (30) (31) . A hypothyroid serum, a normal-TBG euthyroid serum, a 3rd-trimester pregnancy serum (high TBG), and a euthyroid low-TBGII0w-albumln sample were used. The central95% reference range Is depicted by dotted lines. values. In a sample from a totally TBG-deflcient euthyroid subject, the FT4 estimate at 40-fold dilution was still 85% of that in the undiluted serum. Euthyroid and hypothyroid sera with normal TBG (higher T4-binding capacity) were, as expected, more robust in this respect, and their FT4 estimates did not decline significantly until dilutions exceeded 80-fold (16-fold more dilute than in the routine assay). In two subjects with renal failure and one with cardiac disease (NTI), results after the progressive dilution of serum resembled those of other (euthyroid) sera, in these cases (Fig. 4) The assay is therefore compatible with all three kinds of specimens.
Validity of Free Hormone Measurements

Discussion
Like its radioactive counterpart (AmerlexMAB*), the Amerlite-MAB FT4 assay conformed with key criteria for validity in (a) amount of T4 extracted by the antibody and (b) independence from the serum T4-binding proteins (3, 4) . Omitting extra albumin from the assay improved its response to serum dilution (3), without otherwise affecting performance. Sample dilution by the assay ingredients (by fivefold) was deliberately kept low to minimize the effects on FT4 results in patients with severe NTI (12, 13). Conjugation with HRP did not affect the affinity of the antibody for T4. As with the earlier RLA., a solid-phase antibody-binding ligand could be used with a very low binding affinity (3).
In back-substitution reactions, T4 only slowly replaced the solid phase bound to the antibody. The reason is probably similar to that proposed for the Amerlex-FT4 radioassay (3), namely, that high local concentrations of T3 on the solid phase inhibit antibody dissociation once it is bound there. In this respect, the new method resembles the equivalent radioassay, with regard to reference range and discriminatory performance (23 (4, 41, 42 ).
In conclusion, the new FT4 assay, developed with all such problems in mind, retains the simplicity and speed of one-step techniques, while correlating closely in all respects with the results of the two-step approaches. It rightly can be described as a new advance, combining the use of nonradioactive labels with valid technical and diagnostic performance.
